New thiopyrazolo[3,4-d]pyrimidine derivatives as anti-mycobacterial agents

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 6, 2007, Pages 1736-1740

  Ballell, Lluis ^a,b   Field, Robert A ^a   Chung, Gavin A C ^c   Young, Robert J ^c  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b GLAXOSMITHKLINE   (Spain)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Anti mycobacterial; Anti tubercular; SAR; Thiopyrazolopyrimidines

Indexed keywords

ANTIMYCOBACTERIAL AGENT; PYRIMIDINE DERIVATIVE; THIOPYRAZOLO[3,4 D]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ALKYLATION; ANTITUBERCULAR AGENTS; CHEMISTRY, PHYSICAL; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDICATORS AND REAGENTS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PHYSICOCHEMICAL PHENOMENA; PYRAZOLES; PYRIMIDINES; STAPHYLOCOCCUS AUREUS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847055385     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.12.066     Document Type: Article

References (35)

1. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2006. Geneva, Switzerland, ISBN 92-4 156314-1.
2. Williams B.G., and Dye C. Science 301 (2003) 1535
3. Corbett E.L., Watt C.J., Catherine J., Walker N., Maher D., Williams B.G., Raviglione M.C., and Dye C. Arch. Intl. Med. 163 (2003) 1009
4. Septkowitz A., Raffalli J., Riley T., Kiehn T.E., and Armstrong D. Clin. Microbiol. Rev. 8 (1995) 180
5. Recent synthetic leads are reviewed in:. Ballell L., Field R.A., Duncan K., and Young R.J. Antimicrob. Agents Chemother. 49 (2005) 2153
6. Reviewed in:. Duncan K., and Barry C.E. Curr. Opin. Microbiol. 7 (2004) 1
7. Burchenal J.H., Murphy M.L., Ellison R.R., Sykes M.P., Tan T.C., Leone L.A., Karnofsky D.A., Craver L.F., Dargeon H.W., and Rhoads C.P. Blood 8 (1953) 965
8. Elion G.B. J. Med. Virol. (1993) 2
9. Rundles R.W. Arch. Intl. Med. 145 (1985) 1492
10. Chiosis G., Timaul M.N., Lucas B., Munster P.N., Zheng F.F., Sepp-Lorenzino L., and Rosen N. Chem. Biol. 8 (2001) 289
11. Crews C.M., and Mohan R. Curr. Opin. Chem. Biol. 4 (2000) 47
12. Knockaert M., Gray N., Damiens E., Chang Y.-T., Grellier P., Grant K., Fergusson D., Mottram J., Soete M., Dubremetz J.-F., Le Roch K., Doerig C., Schultz P.G., and Meijer L. Chem. Biol. 7 (2000) 411
13. Laufer S.A., Domeyer D.M., Scior T.R., Albrecht W., and Hauser D.R. J. Med. Chem. 48 (2005) 710
14. Armstrong J.I., Portley A.R., Chang Y.-T., Nierengarten D.M., Cook B.N., Bowman K.G., Bishop A., Gray N.S., Shokat K.M., Schultz P.G., and Bertozzi C.R. Angew. Chem. Int. Ed. 39 (2000) 1303
15. Verdugo D.E., Cancilla M.T., Ge X., Gray N.S., Chang Y.-T., Schultz P.G., Negishi M., Leary J.A., and Bertozzi C.R. J. Med. Chem. 44 (2001) 2683
16. Wu X., Ding S., Ding Q., Gray N.S., and Schultz P.G. J. Am. Chem. Soc. 124 (2002) 14521
17. Gundersen L.L., Nissen-Meyer J., and Spilsberg B. J. Med. Chem. 45 (2002) 1383
18. Scozzafava A., Mastrolorenzo A., and Supuran C.T. Bioorg. Med. Chem. Lett. 11 (2001) 1675
19. Klimešová V., Kočí J., Waisser K., and Kaustová J. Il Farmaco 57 (2002) 259
20. Pathak A.K., Pathak V., Seitz L.E., Suling W.J., and Reynolds R.C. J. Med. Chem. 47 (2004) 273
21. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., Pollok B.A., and Connelly P.A. J. Biol. Chem. 271 (1996) 695
22. Traxler P., and Furet P. Pharmacol. Ther. 82 (1999) 195
23. Bergman M.R., and Holycross B.J. J. Pharmacol. Exp. Ther. 279 (1996) 247
24. Ali A., Taylor G.E., Ellsworth K., Harris G., Painter R., Silver L.L., and Young K. J. Med. Chem. 46 (2003) 1824
25. Moukha-Chafiq O., Taha M.L., Lazrek H.B., Barascut J.-L., and Imbach J.-L. CR. Acad. Sci. Paris, Serie IIc, Chimie 3 (2000) 639
26. Adamec J., Waisser K., Kuneŝ J., and Kaustová J. Arch. Pharm. 338 (2005) 385 and references herein
27. 3 (5 mol equiv), filtered to remove the resin and concentrated in vacuo. The bis-alkylated product was purified as described above.
28. The isomeric 2-alkyl-4-(alkylthio)-2H-pyrazolo[3,4-d]pyrimidines were sometimes significant by-products in these syntheses.{A figure is presented}The regioisomers are easily distinguishable by virtue of NOE signals between the heterocycle H-3 proton and N-2 substituents. Such signals are not evident for the N-1-substituted isomer.
29. + 368.0737, found 368.0736.
30. MIC (defined as the lowest concentration of compound producing a >90% reduction in fluorescence observed in a whole cell assay of M. tuberculosis) data were obtained in Middlebrook's 7H11 broth using a microtitre plate Alamar Blue Assay (MABA) as described in:. Collins L., and Franzblau S.G. Antimicrob. Agents Chemother. 41 (1997) 1004
31. Klimešová V., Palát K., Waisser K., and Klimeš J. Int. J. Pharm. 207 (2000) 1
32. Agarwal N., Srivastava P., Raghuwanshi S.K., Upadhyay D.N., Sinha S., Shukla P.K., and Ram V.J. Bioorg. Med. Chem. 10 (2002) 869
33. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Del. Rev. 23 (1997) 3 The Lipinski 'rule of 5' requires that no more than one of the following criteria are met or exceeded: 5 Hydrogen-bond donors, 10 Hydrogen-bond acceptors, molecular weight 500, C log P 5
34. 2 or <12 H-bond donors and acceptors
35. Yoshida F., and Topliss J.G. J. Med. Chem. 43 (2000) 2575 The output from this model suggests four predicted classes of F%, class 1, ≤20%; class 2, 20-49%; class 3, 50-79%; class 4, ≥80%